279 related articles for article (PubMed ID: 29886089)
1. Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort.
Marzouk K; Assel M; Ehdaie B; Vickers A
J Urol; 2018 Dec; 200(6):1250-1255. PubMed ID: 29886089
[TBL] [Abstract][Full Text] [Related]
2. The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer.
Tan HJ; Marks LS; Hoyt MA; Kwan L; Filson CP; Macairan M; Lieu P; Litwin MS; Stanton AL
J Urol; 2016 Jun; 195(6):1724-30. PubMed ID: 26872841
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
Venderbos LD; van den Bergh RC; Roobol MJ; Schröder FH; Essink-Bot ML; Bangma CH; Steyerberg EW; Korfage IJ
Psychooncology; 2015 Mar; 24(3):348-54. PubMed ID: 25138075
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract][Full Text] [Related]
6. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
[TBL] [Abstract][Full Text] [Related]
8. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
9. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Cooley LF; Emeka AA; Meyers TJ; Cooper PR; Lin DW; Finelli A; Eastham JA; Logothetis CJ; Marks LS; Vesprini D; Goldenberg SL; Higano CS; Pavlovich CP; Chan JM; Morgan TM; Klein EA; Barocas DA; Loeb S; Helfand BT; Scholtens DM; Witte JS; Catalona WJ;
J Urol; 2021 Nov; 206(5):1147-1156. PubMed ID: 34503355
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance.
Kang DW; Fairey AS; Boulé NG; Field CJ; Wharton SA; Courneya KS
J Urol; 2022 Apr; 207(4):814-822. PubMed ID: 35179044
[TBL] [Abstract][Full Text] [Related]
12. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
13. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
14. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
15. Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer.
Pham KN; Cullen J; Hurwitz LM; Wolff EM; Levie KE; Odem-Davis K; Banerji JS; Rosner IL; Brand TC; L'Esperance JO; Sterbis JR; Porter CR
J Urol; 2016 Aug; 196(2):392-8. PubMed ID: 26976206
[TBL] [Abstract][Full Text] [Related]
16. Do anxiety and distress increase during active surveillance for low risk prostate cancer?
van den Bergh RC; Essink-Bot ML; Roobol MJ; Schröder FH; Bangma CH; Steyerberg EW
J Urol; 2010 May; 183(5):1786-91. PubMed ID: 20299064
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
18. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
19. The association of cancer-specific anxiety with disease aggressiveness in men on active surveillance of prostate cancer.
Naha U; Freedland SJ; Abern MR; Moreira DM
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):335-340. PubMed ID: 32901094
[TBL] [Abstract][Full Text] [Related]
20. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
